EUCTR2018-000305-23-RO进行中（未招募）1 期
A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women, ages 18 to 70 years, inclusive
- •2. Patients must be mentally capable of giving consent and there must be evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study
- •3. Patients must have SLE as defined by meeting 4 of the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE (with at least 1 clinical and 1 immunologic criterion OR Lupus nephritis as the sole clinical criterion in the presence of antinuclear antibodies [ANA] or anti- double-stranded deoxyribonucleic acid [dsDNA] antibodies), either sequentially or simultaneously
- •4. At screening, patients must have at least 1 of the following:
- •a. Elevated ANA = 1:80 via immunofluorescent assay at the central laboratory
- •b. Positive anti-dsDNA or anti-Smith (Sm) above the normal level as determined by the central laboratory
- •5. At screening, the total SLEDAI-2K score must be = 8, including points from at least 1 of the following clinical components:
- •a. Arthritis, rash, myositis, mucosal ulcers, pleurisy, pericarditis, and vasculitis
- •Note: Points from lupus headache and organic brain syndrome will also be excluded from qualifying total and clinical SLEDAI-2K scores at screening and Day 0.
- •6. A clinical SLEDAI-2K score of = 6 at screening at Day 0. Clinical SLEDAI-2K score is defined as follows:
- •a. Contains points from arthritis, rash, myositis, mucosal ulcers, pleurisy, pericarditis, or vasculitis
- •b. Excludes parameters which require central laboratory results: hematuria, pyuria, urinary casts, proteinuria, positive anti-dsDNA, decreased complement, thrombocytopenia, and leukopenia
- •Note: Points from lupus headache and organic brain syndrome will also be excluded from qualifying total and clinical SLEDAI-2K scores at screening and Day 0.
- •7. Patients must have at least 1 qualifying A or 2Bs from the following manifestations of SLE, as defined by the BILAG criteria as modified for use in this study, which must be confirmed by the central data reviewer:
- •a. BILAG A or B score in the mucocutaneous body system. If a BILAG B score is due to BILAG number 6, mild skin eruption, the CLASI activity score including erythema and scale/hypertrophy must be = 3 excluding points from mucosal ulcers and alopecia.
- •b. BILAG A or B score in the musculoskeletal body system due to active polyarthritis as defined in the protocol Section 4.4
- •Note: Hips, shoulders, back, neck, and temporomandibular joints do not count towards the total number of joints with active synovitis.
- •If only one B” and no A” score is present in the mucocutaneous body system or in the musculoskeletal body system due to arthritis, then at least 1 B” must be present in at least 1 other body system for a total of 2 B” BILAG body system scores.
- •8. Patients must be currently receiving at least 1 of the following:
- •a. Administration for a minimum of 12 weeks, and a stable dose for at least 56 days (8 weeks prior to Day 0) of the following permitted steroid-sparing agents:
- •i. Azathioprine (AZA), mycophenolate mofetil or mycophenolic acid, chloroquine, hydroxychloroquine, or methotrexate (MTX)
- •b. If AZA, myocophenolate mofetil, mycophenolic acid, hydroxychloroquine, or MTX were discontinued prior to screening, the washout period must be = 12 weeks.
- •c. Corticosteroids (prednisone or prednisone-equivalent) at a stable dose of up to 30 mg/day for at least 6 weeks prior to Day 0 (see APPENDIX 3)
- •i. For pati
排除标准
- •1. Drug-induced SLE, rather than idiopathic” SLE
- •2. Other systemic autoimmune disease
- •a. RA-Lupus overlap and secondary Sjögren syndrome are allowed
- •3. Any major surgery within 6 weeks of study drug administration, (Day 0), or any elective surgery planned during the course of the study
- •4. Any history or risk for TB, specifically those with:
- •a. Current clinical, radiographic, or laboratory evidence of active TB
- •b. History of active TB
- •c. Latent TB defined as positive QuantiFERON-TB Gold In-Tube (QFT-G) or other diagnostic test in the absence of clinical manifestations. Latent TB is not excluded if the patient has documented completion of adequate course of prophylactic treatment with regimen recommended by local health authority guideline, or the patient has started treatment with isoniazid, or other regimen recommended by local health authority guidelines for at least 1 month before Day 0 and continues to receive the prophylactic treatment during study until the treatment course is completed
- •5. Active or unstable lupus neuropsychiatric manifestations, including but not limited to any condition defined by BILAG A criteria, with the exception of mononeuritis multiplex and polyneuropathy, which are allowed
- •6. Severe proliferative lupus nephritis, which requires or may require induction treatment with cytotoxic agents or high dose CS
- •7. Concomitant illness that, in the opinion of the investigator,or the sponsor or their designee is likely to require additional systemic glucocorticosteroid therapy during the study, is exclusionary
- •a. However, treatment for asthma with inhalational CS therapy is allowed
- •8. Use or planned use of concomitant medication outside of standard of baseline treatment for SLE from Day -1 or for any time during the study
- •9. Active and clinically significant infection within 60 days prior to first dose of study drug. Clinically significant is defined as requiring systemic parenteral antibiotics or hospitalization
- •10. A history of opportunistic infection, or a history of recurrent or severe disseminated herpes zoster or disseminated herpes simplex within the last 3 years
- •11. Chronic viral hepatitis including hepatitis B and hepatitis C unless patient received curative treatment for HCV and has a documented negative viral load, known human immunodeficiency virus, or acquired immunodeficiency syndrome (AIDS)-related illness
- •12. Cryptosporidium in the stool sample at screening
- •13. White blood cells (WBC) < 1,200/mm3 (1.2 × 109/L) at screening
- •14. Absolute neutrophil count (ANC) < 500/mm3 at screening
- •15. CD4+ count < 150/µL at screening
- •16. Platelets < 50,000/mm3 (50 × 109/L) or < 35,000/ mm3 (35 × 109/L) if related to SLE, at screening
- •17. Hemoglobin < 8 g/dL or < 7 g/dL at screening if related to SLE
- •18. Proteinuria > 3.0 g/day (3000 mg/day) at screening or equivalent level of proteinuria as assessed by protein/creatinine ratio (3 mg/mg or 339 mg/mmol)
- •19. Serum creatinine > 2.0 mg/dL at screening or creatinine clearance (CrCL) < 40 ml/minute based on Cockcroft-Gault calculation
- •20. Serum alanine aminotransferase and/or serum aspartate aminotransferase > 2 × the upper limit of normal at screening, unless explicitly related to lupus based on the investigator’s judgment
- •21. Creatinine kinase > 3.0 × ULN at screening unless related to lupus myositis
- •22. Total bilirubin > 1.5 × ULN at screening
- •23. Any other laboratory test results that, in the opinion of the Investigator or the sponsor or sponsor’s designee, mig
研究者
相似试验
进行中（未招募）
1 期
oSystemic lupus erythematosusEUCTR2018-000305-23-HUBoston Pharmaceuticals, Inc.156
进行中（未招募）
1 期
A Phase 1b/2 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) PatientsSystemic lupus erythematosusEUCTR2018-000305-23-BGBoston Pharmaceuticals, Inc.156
进行中（未招募）
不适用
A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safetyand Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 andHerceptin in Metastatic Breast CancerMedDRA version: 12.0Level: LLTClassification code 10027475Term: Metastatic breast cancerMetastatic breast cancerEUCTR2009-014463-39-GBCelltrion, Inc.170
进行中（未招募）
1 期
This is a study of the effects of CT-P6 and Herceptin in patients with metastatic breast cancer. Patients with metastatic breast cancer who agree to be in this study will receive either CT-P6 or Herceptin in combination with paclitaxel.MedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic breast cancerEUCTR2009-014463-39-BGCelltrion, Inc.170
进行中（未招募）
1 期
A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safetyand Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 andHerceptin in Metastatic Breast CancerMetastatic breast cancerEUCTR2009-014463-39-LVCelltrion, Inc.170